BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 15966562)

  • 1. Current management strategies for hypercalcemia.
    Pecherstorfer M; Brenner K; Zojer N
    Treat Endocrinol; 2003; 2(4):273-92. PubMed ID: 15966562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative tolerability of drug therapies for hypercalcaemia of malignancy.
    Zojer N; Keck AV; Pecherstorfer M
    Drug Saf; 1999 Nov; 21(5):389-406. PubMed ID: 10554053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathophysiology and management of severe hypercalcemia.
    Nussbaum SR
    Endocrinol Metab Clin North Am; 1993 Jun; 22(2):343-62. PubMed ID: 8325291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy.
    Pecherstorfer M; Herrmann Z; Body JJ; Manegold C; Degardin M; Clemens MR; Thürlimann B; Tubiana-Hulin M; Steinhauer EU; van Eijkeren M; Huss HJ; Thiébaud D
    J Clin Oncol; 1996 Jan; 14(1):268-76. PubMed ID: 8558208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia.
    Cvitkovic F; Armand JP; Tubiana-Hulin M; Rossi JF; Warrell RP
    Cancer J; 2006; 12(1):47-53. PubMed ID: 16613662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonates in multiple myeloma: a network meta-analysis.
    Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
    Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review of the role of bisphosphonates in metastatic disease.
    Ross JR; Saunders Y; Edmonds PM; Patel S; Wonderling D; Normand C; Broadley K
    Health Technol Assess; 2004; 8(4):1-176. PubMed ID: 14960258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on the medical treatment of hypercalcemia of malignancy.
    Hall TG; Schaiff RA
    Clin Pharm; 1993 Feb; 12(2):117-25. PubMed ID: 8453860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonates: biological response modifiers in breast cancer.
    Paterson AH
    Clin Breast Cancer; 2002 Aug; 3(3):206-16; discussion 217-8. PubMed ID: 12196279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The diagnosis and management of hypercalcaemia.
    Koh LK
    Ann Acad Med Singap; 2003 Jan; 32(1):129-39. PubMed ID: 12625112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and future directions in medical therapy: hypercalcemia.
    Body JJ
    Cancer; 2000 Jun; 88(12 Suppl):3054-8. PubMed ID: 10898351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute management of cancer-related hypercalcemia.
    Chisholm MA; Mulloy AL; Taylor AT
    Ann Pharmacother; 1996 May; 30(5):507-13. PubMed ID: 8740333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of cancer-related hypercalcemia: the role of gallium nitrate.
    Leyland-Jones B
    Semin Oncol; 2003 Apr; 30(2 Suppl 5):13-9. PubMed ID: 12776255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosing regimens and main adverse events of bisphosphonates.
    Body JJ
    Semin Oncol; 2001 Aug; 28(4 Suppl 11):49-53. PubMed ID: 11544576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypercalcemia of malignancy in the palliative care patient: a treatment strategy.
    Kovacs CS; MacDonald SM; Chik CL; Bruera E
    J Pain Symptom Manage; 1995 Apr; 10(3):224-32. PubMed ID: 7543127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A dose-finding study of zoledronate in hypercalcemic cancer patients.
    Body JJ; Lortholary A; Romieu G; Vigneron AM; Ford J
    J Bone Miner Res; 1999 Sep; 14(9):1557-61. PubMed ID: 10469284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypercalcemia: an evidence-based approach to clinical cases.
    Assadi F
    Iran J Kidney Dis; 2009 Apr; 3(2):71-9. PubMed ID: 19395781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review of bisphosphonates for hypercalcaemia of malignancy.
    Saunders Y; Ross JR; Broadley KE; Edmonds PM; Patel S;
    Palliat Med; 2004 Jul; 18(5):418-31. PubMed ID: 15332420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The efficacy and safety of intravenous bisphosphonates in the treatment of primary hyperparathyroidism complicated by hypercalcemia crisis].
    Han GY; Wang O; Xing XP; Meng XW; Lian XL; Guan H; Ye W; Xia WB; Li M; Jiang Y; Hu YY; Liu HC; Cui QC
    Zhonghua Nei Ke Za Zhi; 2009 Sep; 48(9):729-33. PubMed ID: 20079207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonates for Paget's disease of bone in adults.
    Corral-Gudino L; Tan AJ; Del Pino-Montes J; Ralston SH
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD004956. PubMed ID: 29192423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.